Cell Therapeutics gets pacritinib partner in Baxter

Cell Therapeutics (CTIC) and Baxter (BAX) enter into a licensing agreement for the development and commercialization of pacritinib (the JAK2/FLT3 inhibitor that's currently in Phase 3 testing for myelofibrosis).

Terms: Upfront payment to CTIC of $60M, $30M of which is an equity investment; CTIC eligible for milestone payments up to $112M and sales milestone payments assuming approval; CTIC gets royalties on sales outside the U.S., where BAX has assumed commercialization rights; the two companies will jointly commercialize the drug in the U.S.

BAX will book a $30M pre-tax R&D charge in Q4.

CTIC calls BAX "the ideal strategic partner." (PR)

On watch today are shares of Incyte (INCY), whose Jakafi may see some competition from pacritinib, although it isn't clear how much of a dent pacritinib will make.

From other sites
Comments (1)
  • jacosa
    , contributor
    Comments (219) | Send Message
    Drug may well find a market, but probably not a candidate to become first-line treatment for MF because the anti JAK-1 activity of Jakafi, the incumbent, reduces morbidity. Also, the pneumonia signal seen in early pacritinib trials is a concern.
    15 Nov 2013, 09:13 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs